8/26/2023 0 Comments Keynote 407These findings confirm that the addition of pembrolizumab to frontline chemotherapy induces prolonged survival benefit at 3 years in patients with metastatic squamous NSCLC, concludes Robinson. The 3-year OS rates were 29.7% vs 18.2%, respectively. Maintenance pembrolizumab or placebo was. pivotal, Phase 3 KEYNOTE-407 trial, which enrolled patients regardless of PD-L1 tumor expression status. 1 Individuals were randomly assigned to receive four cycles of carboplatin and paclitaxel or nabpaclitaxel, plus either pembrolizumab or placebo. En el ensayo KEYNOTE-407, el tratamiento de primera línea con pembrolizumab en combinación con quimioterapia condujo a mejoras significativas de la supervivencia global en pacientes con cáncer de pulmón no microcítico metastásico de células escamosas, independientemente de la expresión de PD-L1, indicó el Dr. At a median of 40.1 months from randomization to data cutoff, the median overall survival (OS) was 17.2 months with pembrolizumab plus chemotherapy vs 11.6 months with chemotherapy alone. The global phase III KEYNOTE-407 trial included 559 patients with squamous NSCLC without regard to tumor PD-L1 expression levels. Robinson, MD, MSc, FRCPC, associate professor, Department of Oncology, Queen’s University School of Medicine, attending staff, Kingston General Hospital, attending staff, Hotel Dieu Hospital, discusses the updated results of the phase 3 KEYNOTE-407 trial in squamous non–small cell lung cancer (NSCLC).ĭuring the 2021 European Lung Cancer Virtual Congress, updated findings from the KEYNOTE-407 trial were presented, demonstrating sustained and durable benefit with the combination of pembrolizumab (Keytruda) and chemotherapy vs chemotherapy alone without additional toxicity. Introduction: In the randomized KEYNOTE-407 study (, NCT02775435), pembrolizumab plus carboplatin and paclitaxel/nab-paclitaxel (chemotherapy) significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus chemotherapy in patients with previously untreated metastatic squamous NSCLC.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |